Skip to main content
Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet Only preliminary foundational data below
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Eikon Therapeutics, Inc. (EIKN) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysis — the core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at delvantic.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Eikon Therapeutics, Inc.

EIKN NASDAQ GICS Category PDF
Healthcare · Biotechnology
Millbrae, CA 94030, United States eikontx.com Updated Aug 11, 9:58am
Price
$9.96
Market Cap
$526.8M
Employees
384
Beta
—
Avg Volume
344,694
CEO
Dr. Roger M. Perlmutter M.D., Ph.D.

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company pioneering advanced drug discovery through visualization of protein motion in living cells. Founded in 2019 and headquartered in Millbrae, California, it employs 384 people and focuses on developing therapies primarily for cancer treatment using innovative imaging techniques. The company integrates cutting-edge technology to observe dynamic protein behaviors, aiming to revolutionize how drugs are identified and optimized for oncology indications. Key leadership includes CEO Roger Perlmutter, co-founders Xavier Darzacq, Robert Tjian, and Eric Betzig, alongside experts like Chief Scientific Officer Dan Anderson and Chief Medical Officer Roy Baynes. Supported by prominent investors such as T. Rowe Price, Lux Capital, General Catalyst, and Foresite Capital, Eikon Therapeutics has raised substantial funding through multiple rounds, including a $351 million Series B in 2025. Operating in the biological products sector, it plays a significant role in advancing precision medicine for challenging diseases.

Runs with full report
Recent SEC Filings
Filed Form Document
Aug 6, 2026 SCHEDULE 13G/A View
Aug 3, 2026 8-K View
Jun 15, 2026 3 View
Jun 10, 2026 8-K View
Jun 1, 2026 8-K View
May 15, 2026 SCHEDULE 13G View
May 13, 2026 SCHEDULE 13G View
May 11, 2026 10-Q View
May 11, 2026 8-K View
May 6, 2026 SCHEDULE 13G View
Apr 29, 2026 SCHEDULE 13G View
Mar 30, 2026 8-K View

Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.

Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Aug 11, 2026 9:58am (just now)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for EIKN — it's generated by the pipeline (market-narrative step).
Claude Reading
Claude Opus reviews the pipeline's raw data + every prior verdict, then writes an independent take.
No AI findings yet for EIKN — they're generated by the pipeline (ai-findings step) when a report is run on this ticker.
GPT Reading
GPT reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No GPT reading yet for EIKN — it's generated by the pipeline (gpt-critique step) after the other Big-3 seats, when a report is run on this ticker.
Grok Reading
Grok (xAI) reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No Grok reading yet for EIKN — it's generated by the pipeline (grok-critique step) alongside the other Big-3 seats, when a report is run on this ticker.
Advanced Analysis Forensic deep-dive · four lenses
A separate, manually-run forensic pipeline (dilution, earnings quality, liquidity → two scored lenses → the play). Hasn't been run for this ticker yet.
Community AI Feedback
No community reviews yet for EIKN. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.525 · a5aac093 · 2026-08-10 20:52:14